Management of in- and out-of-hospital screening for hepatitis C
- PMID: 36761331
- PMCID: PMC9905736
- DOI: 10.3389/fpubh.2022.984810
Management of in- and out-of-hospital screening for hepatitis C
Abstract
Because of insidious progression and no significant clinical symptoms at early stage, chronic hepatitis C (CHC) is often diagnosed after the occurrence of cirrhosis and hepatocellular carcinoma. Highly effective and low drug resistance of direct-acting antiviral agents (DAAs) have enabled cure of CHC, encouraging the World Health Organization to propose a global viral hepatitis elimination program. To Date, vaccine for CHC is still under research. Therefore, reducing the source of infection is an important means of eliminating CHC other than cutting off the transmission route, which requires screening, diagnosing and treating as many patients in the population as possible. Hospital-based screening strategy have been found to be cost-effective in the management of CHC screening, as reported both nationally and internationally. Currently, China has issued In-hospital process for viral hepatitis C screening and management in China (Draft) in April, 2021, which provides a standardized implementation process and direction for in-hospital hepatitis C screening and treatment, but still requires medical institution to develop its own management process, taking into account its current situation and learning from domestic and international experience. In addition, screening for CHC outside the hospital among special populations, such as blood donors, pregnant women, homosexuals, intravenous drug users, prisoners, and residents in rural areas with scarce medical care resources, also requires attention and development of targeted and rational screening strategies. In this paper, we analyze and recommend the management of hepatitis C screening from both in-hospital and out-of-hospital perspectives, with the aim of contributing to the formulation of hepatitis C screening strategies.
Keywords: hepatitis C; in-hospital; out-of-hospital; screening; special populations.
Copyright © 2023 Zhou, Wang, Li and Chen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
[In-hospital process for viral hepatitis C screening and management in China (Draft)].Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):319-325. doi: 10.3760/cma.j.cn501113-20210401-00157. Zhonghua Gan Zang Bing Za Zhi. 2021. PMID: 33979957 Chinese.
-
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.J Hepatol. 2019 Dec;71(6):1076-1085. doi: 10.1016/j.jhep.2019.07.006. Epub 2019 Jul 17. J Hepatol. 2019. PMID: 31325468 Clinical Trial.
-
Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review.JNMA J Nepal Med Assoc. 2021 Sep 11;59(241):942-953. doi: 10.31729/jnma.5501. JNMA J Nepal Med Assoc. 2021. PMID: 35199739 Free PMC article. Review.
-
Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children.Klin Padiatr. 2021 Sep;233(5):211-215. doi: 10.1055/a-1304-3542. Epub 2020 Dec 18. Klin Padiatr. 2021. PMID: 33339066 Review. English.
-
Planning the hepatitis C virus elimination in Cyprus: A modeling study.World J Gastroenterol. 2021 Aug 21;27(31):5219-5231. doi: 10.3748/wjg.v27.i31.5219. World J Gastroenterol. 2021. PMID: 34497446 Free PMC article.
Cited by
-
Current perspectives of viral hepatitis.World J Gastroenterol. 2024 May 14;30(18):2402-2417. doi: 10.3748/wjg.v30.i18.2402. World J Gastroenterol. 2024. PMID: 38764770 Free PMC article. Review.
-
Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment.Life (Basel). 2023 Sep 26;13(10):1964. doi: 10.3390/life13101964. Life (Basel). 2023. PMID: 37895346 Free PMC article. Review.
-
Burden of Hepatocellular Carcinoma and Its Underlying Etiologies in China, 1990-2021: Findings From the Global Burden of Disease Study 2021.Cancer Control. 2024 Jan-Dec;31:10732748241310573. doi: 10.1177/10732748241310573. Cancer Control. 2024. PMID: 39703050 Free PMC article.
-
Pathway to hepatitis C elimination: insights from a large tertiary hospital in South China.Ann Med. 2025 Dec;57(1):2464931. doi: 10.1080/07853890.2025.2464931. Epub 2025 Feb 12. Ann Med. 2025. PMID: 39936217 Free PMC article.
-
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virol J. 2025 Aug 11;22(1):274. doi: 10.1186/s12985-025-02907-3. Virol J. 2025. PMID: 40790753 Free PMC article. Review.
References
-
- Galbraith JW, Anderson ES, Hsieh YH, Franco RA, Donnelly JP, Rodgers JB, et al. . High prevalence of hepatitis c infection among adult patients at four urban emergency departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017. MMWR. (2020) 69:569–74. 10.15585/mmwr.mm6919a1 - DOI - PMC - PubMed
-
- Williams J, Vickerman P, Douthwaite S, Nebbia G, Hunter L, Wong T, et al. . An economic evaluation of the cost-effectiveness of opt-out hepatitis B and hepatitis C testing in an emergency department setting in the United Kingdom. Value Health. (2020) 23:1003–11. 10.1016/j.jval.2020.03.014 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous